Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs

ClinicalTrials.gov ID: NCT00241553

Public ClinicalTrials.gov record NCT00241553. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Efficacy of Esomeprazole 40 mg Once Daily Versus Placebo or Esomeprazole 20 mg Once Daily Versus Placebo in Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs Including COX-2 Selective NSAIDs

Study identification

NCT ID
NCT00241553
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
276 participants

Conditions and interventions

Interventions

  • Esomeprazole Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 2001
Primary completion
Jan 31, 2003
Completion
Jan 31, 2003
Last update posted
Jan 23, 2011

2001 – 2003

United States locations

U.S. sites
31
U.S. states
17
U.S. cities
31
Facility City State ZIP Site status
Research Site Tallassee Alabama
Research Site Phoenix Arizona
Research Site Garden Grove California
Research Site Orange California
Research Site Bradenton Florida
Research Site Coral Gables Florida
Research Site Hollywood Florida
Research Site St. Petersburg Florida
Research Site Tavares Florida
Research Site Zephyrhills Florida
Research Site Nampa Idaho
Research Site Elkhart Indiana
Research Site Evansville Indiana
Research Site Newburgh Indiana
Research Site Wichita Kansas
Research Site Hollywood Maryland
Research Site Butte Montana
Research Site Princeton New Jersey
Research Site Toms River New Jersey
Research Site Endwell New York
Research Site Hewlett New York
Research Site Charlotte North Carolina
Research Site Winston-Salem North Carolina
Research Site Duncansville Pennsylvania
Research Site Erie Pennsylvania
Research Site Jackson Tennessee
Research Site Waco Texas
Research Site Edmonds Washington
Research Site Olympia Washington
Research Site Greenfield Wisconsin
Research Site Milwaukee Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 105 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00241553, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 23, 2011 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00241553 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →